Amalgamated Bank grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,564 shares of the life sciences company’s stock after purchasing an additional 388 shares during the quarter. Amalgamated Bank’s holdings in Illumina were worth $3,499,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after acquiring an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Illumina by 3.1% in the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after acquiring an additional 76,452 shares during the last quarter. Capital World Investors lifted its stake in Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC purchased a new position in Illumina in the second quarter worth approximately $211,584,000. 91.76% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Citigroup raised their price objective on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, October 25th. Barclays raised their price objective on shares of Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Bank of America raised their price objective on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reissued a “market perform” rating and set a $205.00 price objective (up previously from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $200.88.

In other news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $200.16, for a total value of $4,003,200.00. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $107,921,468.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of Illumina stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00. Following the completion of the transaction, the executive vice president now directly owns 30,370 shares in the company, valued at $6,240,427.60. The disclosure for this sale can be found here. Insiders sold a total of 161,360 shares of company stock worth $33,599,137 over the last ninety days. Corporate insiders own 0.89% of the company’s stock.

Illumina, Inc. (NASDAQ:ILMN) opened at $227.48 on Thursday. The company has a market cap of $33,036.88, a price-to-earnings ratio of 66.16, a PEG ratio of 3.74 and a beta of 0.74. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $227.85. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 EPS. analysts predict that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/30/amalgamated-bank-acquires-388-shares-of-illumina-inc-ilmn.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.